Ponatinib in Refractory Philadelphia Chromosome-positive Leukemias

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2012 Nov 30

PMID 23190221

Citations 308

Authors

Jorge E Cortes

Hagop Kantarjian

Neil P Shah

Dale Bixby

Michael J Mauro

Ian Flinn

Thomas OHare

Simin Hu

Narayana I Narasimhan

Victor M Rivera

Tim Clackson

Christopher D Turner

Frank G Haluska

Brian J Druker

Michael W N Deininger

Moshe Talpaz

Affiliations

Soon will be listed here.

Abstract

Background: Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mutations in the BCR-ABL kinase domain. Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T315I, which is uniformly resistant to tyrosine kinase inhibitors.

Methods: In this phase 1 dose-escalation study, we enrolled 81 patients with resistant hematologic cancers, including 60 with CML and 5 with Ph-positive ALL. Ponatinib was administered once daily at doses ranging from 2 to 60 mg. Median follow-up was 56 weeks (range, 2 to 140).

Results: Dose-limiting toxic effects included elevated lipase or amylase levels and pancreatitis. Common adverse events were rash, myelosuppression, and constitutional symptoms. Among Ph-positive patients, 91% had received two or more approved tyrosine kinase inhibitors, and 51% had received all three approved tyrosine kinase inhibitors. Of 43 patients with chronic-phase CML, 98% had a complete hematologic response, 72% had a major cytogenetic response, and 44% had a major molecular response. Of 12 patients who had chronic-phase CML with the T315I mutation, 100% had a complete hematologic response and 92% had a major cytogenetic response. Of 13 patients with chronic-phase CML without detectable mutations, 100% had a complete hematologic response and 62% had a major cytogenetic response. Responses among patients with chronic-phase CML were durable. Of 22 patients with accelerated-phase or blast-phase CML or Ph-positive ALL, 36% had a major hematologic response and 32% had a major cytogenetic response.

Conclusions: Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations. (Funded by Ariad Pharmaceuticals and others; ClinicalTrials.gov number, NCT00660920.).

Citing Articles

Antibody-Based and Other Novel Agents in Adult B-Cell Acute Lymphoblastic Leukemia.

Csizmar C, Litzow M, Saliba A Cancers (Basel). 2025; 17(5).

PMID: 40075627 PMC: 11899621. DOI: 10.3390/cancers17050779.

Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study.

Hanley M, Larson T, Diderichsen P, Largajolli A, Hui K, Srimani J Clin Transl Sci. 2025; 18(3):e70175.

PMID: 40025846 PMC: 11873365. DOI: 10.1111/cts.70175.

Bosutinib-Induced Pleural Effusion-Class Effect and Cross-Intolerance to All Tyrosine Kinase Inhibitors.

Vojjala N, Sami H, Kotla N, Peshin S, Goyal K, Kondaveety S Hematol Rep. 2025; 17(1).

PMID: 39997355 PMC: 11855369. DOI: 10.3390/hematolrep17010007.

Off-label use of anlotinib in malignancies' treatment: efficacy and management of adverse reactions.

Wang G, Wang Y, Jin C, Sun X Pharmacol Rep. 2025; .

PMID: 39899257 DOI: 10.1007/s43440-025-00700-1.

Sensitivity to Tyrosine Kinase Inhibitors in a Human Philadelphia Chromosome-Positive (Ph+) Leukemia Model With the T315I-Inclusive Compound Mutation.

Nguyen T, Tamai M, Harama D, Kagami K, Komatsu C, Kasai S Cureus. 2025; 16(12):e76538.

PMID: 39872583 PMC: 11772067. DOI: 10.7759/cureus.76538.

References

Branford S, Fletcher L, Cross N, Muller M, Hochhaus A, Kim D . Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008; 112(8):3330-8. DOI: 10.1182/blood-2008-04-150680. View

Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A . Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006; 12(24):7374-9. DOI: 10.1158/1078-0432.CCR-06-1516. View

Oken M, Creech R, Tormey D, Horton J, Davis T, McFadden E . Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5(6):649-55. View

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

Khoury H, Cortes J, Kantarjian H, Gambacorti-Passerini C, Baccarani M, Kim D . Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012; 119(15):3403-12. PMC: 4916559. DOI: 10.1182/blood-2011-11-390120. View

OHare T, Shakespeare W, Zhu X, Eide C, Rivera V, Wang F . AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009; 16(5):401-12. PMC: 2804470. DOI: 10.1016/j.ccr.2009.09.028. View

Kantarjian H, Hochhaus A, Saglio G, de Souza C, Flinn I, Stenke L . Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12(9):841-51. DOI: 10.1016/S1470-2045(11)70201-7. View

Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346(9):645-52. DOI: 10.1056/NEJMoa011573. View

Kummar S, Gutierrez M, Doroshow J, Murgo A . Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol. 2006; 62(1):15-26. PMC: 1885070. DOI: 10.1111/j.1365-2125.2006.02713.x. View

10.

Cheson B, Bennett J, Grever M, Kay N, Keating M, OBrien S . National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87(12):4990-7. View

11.

Saglio G, Kim D, Issaragrisil S, le Coutre P, Etienne G, Lobo C . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-9. DOI: 10.1056/NEJMoa0912614. View

12.

Gozgit J, Wong M, Moran L, Wardwell S, Mohemmad Q, Narasimhan N . Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther. 2012; 11(3):690-9. DOI: 10.1158/1535-7163.MCT-11-0450. View

13.

Daley G, Van Etten R, Baltimore D . Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990; 247(4944):824-30. DOI: 10.1126/science.2406902. View

14.

Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J . Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003; 102(1):276-83. DOI: 10.1182/blood-2002-09-2896. View

15.

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27(35):6041-51. PMC: 4979100. DOI: 10.1200/JCO.2009.25.0779. View

16.

Zhou T, Commodore L, Huang W, Wang Y, Thomas M, Keats J . Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des. 2010; 77(1):1-11. DOI: 10.1111/j.1747-0285.2010.01054.x. View

17.

Ibrahim A, Paliompeis C, Bua M, Milojkovic D, Szydlo R, Khorashad J . Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy. Blood. 2010; 116(25):5497-500. PMC: 6143154. DOI: 10.1182/blood-2010-06-291922. View

18.

de Lavallade H, Apperley J, Khorashad J, Milojkovic D, Reid A, Bua M . Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26(20):3358-63. DOI: 10.1200/JCO.2007.15.8154. View

19.

Quintas-Cardama A, Kantarjian H, Cortes J . Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control. 2009; 16(2):122-31. DOI: 10.1177/107327480901600204. View

20.

Garg R, Kantarjian H, OBrien S, Quintas-Cardama A, Faderl S, Estrov Z . The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood. 2009; 114(20):4361-8. PMC: 3952810. DOI: 10.1182/blood-2009-05-221531. View